Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 15, Issue 4, Pages 299-311
Publisher
Informa UK Limited
Online
2019-03-02
DOI
10.1080/17425255.2019.1588885
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
- (2019) Maria Carolina Ruiz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
- (2018) Hadeel Obiedat et al. BMC Medical Genetics
- Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines
- (2018) Maria Ferraiuolo et al. CANCER LETTERS
- Synthesis, characterization, and cytotoxic properties of mono- and di-nuclear cobalt(ii)-polypyridyl complexes
- (2018) Arvin Eskandari et al. DALTON TRANSACTIONS
- A Potential Bone-Targeting Hypotoxic Platinum(II) Complex with an Unusual Cytostatic Mechanism toward Osteosarcoma Cells
- (2018) Zhenqin Zhang et al. INORGANIC CHEMISTRY
- Current and future therapeutic approaches for osteosarcoma
- (2017) Douglas J. Harrison et al. Expert Review of Anticancer Therapy
- Genome-wide association study identifies the GLDC /IL33 locus associated with survival of osteosarcoma patients
- (2017) Roelof Koster et al. INTERNATIONAL JOURNAL OF CANCER
- Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis
- (2017) Haiguang Zhang et al. World Journal of Surgical Oncology
- Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis
- (2017) Xueyong Liu et al. Oncotarget
- The role of pharmacogenetics in the treatment of osteosarcoma
- (2016) Hanneke I. Vos et al. DRUG DISCOVERY TODAY
- A meta-analysis of association between glutathione S-transferase gene polymorphism and osteosarcoma chemosensitivity in Chinese population
- (2016) Haiya Zheng et al. Journal of Cancer Research and Therapeutics
- Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial
- (2016) Sophie Piperno-Neumann et al. LANCET ONCOLOGY
- Monogenic and polygenic determinants of sarcoma risk: an international genetic study
- (2016) Mandy L Ballinger et al. LANCET ONCOLOGY
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
- (2016) Neyssa M Marina et al. LANCET ONCOLOGY
- Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients
- (2016) Claudia M Hattinger et al. PHARMACOGENOMICS
- The pharmacogenomics of osteosarcoma
- (2016) M Serra et al. PHARMACOGENOMICS JOURNAL
- Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
- (2016) Claudia M. Hattinger et al. Oncotarget
- Quantitative Assessment of the Association between ABC Polymorphisms and Osteosarcoma Response: a Meta-analysis
- (2015) Xu Chen et al. Asian Pacific Journal of Cancer Prevention
- Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma
- (2015) Katja Goričar et al. Cancer Epidemiology
- A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
- (2015) M. M. Hagleitner et al. CLINICAL CANCER RESEARCH
- Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma
- (2015) Claudia Maria Hattinger et al. Expert Opinion on Drug Metabolism & Toxicology
- Advances in emerging drugs for osteosarcoma
- (2015) Claudia Maria Hattinger et al. EXPERT OPINION ON EMERGING DRUGS
- An update on chemotherapy for osteosarcoma
- (2015) Stefano Ferrari et al. EXPERT OPINION ON PHARMACOTHERAPY
- Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma
- (2015) M.J. Wang et al. GENETICS AND MOLECULAR RESEARCH
- Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma
- (2015) Z.H. Cao et al. GENETICS AND MOLECULAR RESEARCH
- Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma
- (2015) Q. Zhang et al. GENETICS AND MOLECULAR RESEARCH
- Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma
- (2015) Z.F. Liu et al. GENETICS AND MOLECULAR RESEARCH
- Germline Mutations in Predisposition Genes in Pediatric Cancer
- (2015) Jinghui Zhang et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma
- (2015) L. Mirabello et al. Cancer Discovery
- DNA repair mechanisms in cancer development and therapy
- (2015) Alessandro Torgovnick et al. Frontiers in Genetics
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†
- (2014) J. S. Whelan et al. ANNALS OF ONCOLOGY
- Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments
- (2014) Carson Ka-Lok Lo et al. BMC Medical Research Methodology
- The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis
- (2014) Z. Wang et al. EUROPEAN JOURNAL OF CANCER CARE
- Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy
- (2014) J.Z. Li et al. GENETICS AND MOLECULAR RESEARCH
- ERCC polymorphisms and prognosis of patients with osteosarcoma
- (2014) Jinsong Li et al. TUMOR BIOLOGY
- Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy
- (2014) Shizhang Liu et al. TUMOR BIOLOGY
- Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor
- (2013) Li-Min Yang et al. Asian Pacific Journal of Cancer Prevention
- Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients
- (2013) Ting Hao et al. Asian Pacific Journal of Cancer Prevention
- Predictive Impact of Common Variations in DNA Repair Genes on Clinical Outcome of Osteosarcoma
- (2013) Sheng-Bin Bai et al. Asian Pacific Journal of Cancer Prevention
- Effect of Variation of ABCB1 and ABCC3 Genotypes on the Survival of Bone Tumor Cases after Chemotherapy
- (2013) Jie Yang et al. Asian Pacific Journal of Cancer Prevention
- Single Nucleotide Polymorphisms in the NER Pathway and Clinical Outcome of Patients with Bone Malignant Tumor
- (2013) Xiao-Hui Sun et al. Asian Pacific Journal of Cancer Prevention
- Genome-wide association study identifies two susceptibility loci for osteosarcoma
- (2013) Sharon A Savage et al. NATURE GENETICS
- Predictive Potential of Glutathione S-Transferase Polymorphisms for Prognosis of Osteosarcoma Patients on Chemotherapy
- (2012) Shai-Lin Zhang et al. Asian Pacific Journal of Cancer Prevention
- Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma
- (2011) Rachael E. Windsor et al. CANCER
- Drug transporters of platinum-based anticancer agents and their clinical significance
- (2011) Herman Burger et al. DRUG RESISTANCE UPDATES
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
- (2011) Jakob K. Anninga et al. EUROPEAN JOURNAL OF CANCER
- The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity
- (2011) Rui Gao et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy
- (2011) P Biason et al. PHARMACOGENOMICS JOURNAL
- Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study
- (2011) Daniela Caronia et al. PLoS One
- Glutathione S-transferase polymorphisms in osteosarcoma patients
- (2010) Carolina Salinas-Souza et al. Pharmacogenetics and Genomics
- Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients
- (2009) D Caronia et al. PHARMACOGENOMICS JOURNAL
- DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
- (2008) Howard Lieberman CURRENT MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started